Sensei biotherapeutics announces initiation of combination arm for phase 1/2 clinical study of sns-101 with regeneron's libtayo®

- eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - monotherapy arm has advanced to a fourth cohort, with initial monotherapy pk and safety data expected in the fourth quarter of 2023 and topline monotherapy data expected in 2024 - - new guidance for initial combination pk and safety data expected in the first quarter of 2024, with preliminary anti-tumor activity data expected in 2024 - boston, sept. 27, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the first patient has been dosed in the combination therapy arm of the phase 1/2 clinical trial for sns-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint vista (v-domain ig suppressor of t cell activation).
SNSE Ratings Summary
SNSE Quant Ranking